| A novel methodology for large-scale phylogeny partition MCF Prosperi, M Ciccozzi, I Fanti, F Saladini, M Pecorari, V Borghi, ... Nature communications 2 (1), 321, 2011 | 141 | 2011 |
| SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19 I Vicenti, M Zazzi, F Saladini Expert Opinion on Therapeutic Patents 31 (4), 325-337, 2021 | 123 | 2021 |
| Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents A Brai, R Fazi, C Tintori, C Zamperini, F Bugli, M Sanguinetti, E Stigliano, ... Proceedings of the National Academy of Sciences 113 (19), 5388-5393, 2016 | 119 | 2016 |
| Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge F Picarazzi, I Vicenti, F Saladini, M Zazzi, M Mori Molecules 25 (23), 5695, 2020 | 85 | 2020 |
| Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with … R Gagliardini, A Ciccullo, A Borghetti, F Maggiolo, D Bartolozzi, V Borghi, ... Open forum infectious diseases 5 (6), ofy113, 2018 | 79 | 2018 |
| Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy I Vicenti, A Rosi, F Saladini, G Meini, F Pippi, B Rossetti, L Sidella, ... Journal of antimicrobial chemotherapy 67 (4), 984-987, 2012 | 68 | 2012 |
| Changing patterns in HIV‐1 non‐B clade prevalence and diversity in Italy over three decades* A Lai, C Riva, A Marconi, M Balestrieri, F Razzolini, G Meini, I Vicenti, ... HIV medicine 11 (9), 593-602, 2010 | 65 | 2010 |
| Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro I Vicenti, A Boccuto, A Giannini, F Dragoni, F Saladini, M Zazzi Virus research 244, 64-70, 2018 | 56 | 2018 |
| Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors A De Luca, S Di Giambenedetto, A Lo Presti, S Sierra, M Prosperi, E Cella, ... Open forum infectious diseases 2 (2), ofv043, 2015 | 52 | 2015 |
| Synthesis and antiviral activity of novel 1, 3, 4-thiadiazole inhibitors of DDX3X A Brai, S Ronzini, V Riva, L Botta, C Zamperini, M Borgini, CI Trivisani, ... Molecules 24 (21), 3988, 2019 | 45 | 2019 |
| Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro F Dragoni, A Boccuto, F Picarazzi, A Giannini, F Giammarino, F Saladini, ... Antiviral research 175, 104708, 2020 | 39 | 2020 |
| Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 B Rossetti, S Di Giambenedetto, C Torti, MC Postorino, G Punzi, ... HIV medicine 19 (9), 619-628, 2018 | 39 | 2018 |
| Identification of a possible ancestor of the subtype A1 HIV Type 1 variant circulating in the former Soviet Union C Riva, L Romano, F Saladini, A Lai, JK Carr, D Francisci, C Balotta, ... AIDS research and human retroviruses 24 (10), 1319-1325, 2008 | 36 | 2008 |
| Discovery and structure-based optimization of 2-Ureidothiophene-3-carboxylic acids as dual bacterial RNA polymerase and viral reverse transcriptase inhibitors WAM Elgaher, KK Sharma, J Haupenthal, F Saladini, M Pires, E Real, ... Journal of Medicinal Chemistry 59 (15), 7212-7222, 2016 | 35 | 2016 |
| DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins A Brai, V Riva, F Saladini, C Zamperini, CI Trivisani, A Garbelli, C Pennisi, ... European Journal of Medicinal Chemistry 200, 112319, 2020 | 33 | 2020 |
| Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors G Sterrantino, V Borghi, AP Callegaro, B Bruzzone, F Saladini, ... International journal of antimicrobial agents 53 (4), 515-519, 2019 | 33 | 2019 |
| Agreement between an in‐house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV‐1 protease, reverse … F Saladini, A Giannini, A Boccuto, I Vicenti, M Zazzi Journal of Clinical Laboratory Analysis 32 (1), e22206, 2018 | 33 | 2018 |
| Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects I Vicenti, F Razzolini, F Saladini, L Romano, M Zazzi Clinical infectious diseases 44 (12), 1657-1661, 2007 | 30 | 2007 |
| Prevalence of HIV‐1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients F Saladini, G Meini, C Bianco, L Monno, G Punzi, M Pecorari, V Borghi, ... Clinical Microbiology and Infection 18 (10), E428-E430, 2012 | 26 | 2012 |
| Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database F Lombardi, A Giacomelli, D Armenia, A Lai, A Dusina, A Bezenchek, ... International journal of antimicrobial agents 57 (2), 106252, 2021 | 23 | 2021 |
